Evidence map›Paper›PMID 40807333›Full record

ReviewMolecules (Basel, Switzerland)2025

Natural Neuroinflammatory Modulators: Therapeutic Potential of Fungi-Derived Compounds in Selected Neurodegenerative Diseases.

Agnieszka Godela, Diana Rogacz, Barbara Pawłowska, Robert Biczak

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Transcriptional Reprogramming of Cancer Metabolism:International journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Agnieszka GodelaThe Faculty of Science and Technology, Jan Długosz University in Czestochowa, 13/15 Armii Krajowej Av., 42-200 Czestochowa, Poland.
Diana RogaczThe Faculty of Science and Technology, Jan Długosz University in Czestochowa, 13/15 Armii Krajowej Av., 42-200 Czestochowa, Poland.
Barbara PawłowskaThe Faculty of Science and Technology, Jan Długosz University in Czestochowa, 13/15 Armii Krajowej Av., 42-200 Czestochowa, Poland.ORCID 0000-0002-5314-920X
Robert BiczakThe Faculty of Science and Technology, Jan Długosz University in Czestochowa, 13/15 Armii Krajowej Av., 42-200 Czestochowa, Poland.ORCID 0000-0003-2458-0217

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis remain incurable. Current therapeutic strategies primarily focus on slowing disease progression, alleviating symptoms, and improving patients' quality of life, including the management of comorbid conditions. Over the past few decades, the incidence of diagnosed neurodegenerative disorders has risen significantly. As the number of affected individuals continues to grow, so does the urgent need for effective treatments that can halt or mitigate the progression of these diseases. Among the most promising therapeutic resources are bioactive compounds derived from fungi. The high quality of proteins, polysaccharides, unsaturated fatty acids, triterpenoids, sterols, and secondary metabolites found in fungi have attracted growing interest from researchers across multiple disciplines. One intensively studied direction involves the use of naturally occurring fungi-derived nutraceuticals in the treatment of various diseases, including neurodegenerative conditions. This article provides an overview of recent findings on fungal compounds-such as phenolic compounds, carbohydrates, peptides and proteins, and lipids-that may have potential applications in the treatment of neurodegenerative diseases and the alleviation of their symptoms.

Indexed as

Biological ProductsFungiNeurodegenerative DiseasesAnimalsHumansBiological Productsbioactive metabolitesfunginatural nutraceuticalsneurodegenerative diseasesneuroinflammationneuroprotection

Identifiers

PMID40807333
PMCPMC12348897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.